WEE1 and breast carcinoma: A Phase I/II Trial of an Oral MTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, TarcevaTM) In Patients With Metastatic Breast Cancer